NewsPatient ExperienceMedline brings game-changing Visby STI test to healthcare organizations

Medline brings game-changing Visby STI test to healthcare organizations

Innovative handheld PCR test helps clinicians detect STIs faster

By Medline Newsroom Staff | August 2, 2022

Patient Experience

Medline brings game-changing Visby STI test to healthcare organizations

Innovative handheld PCR test helps clinicians detect STIs faster

VISBY STI

As sexually transmitted infections (STIs) are at an all-time high for the sixth consecutive year in the U.S., Medline will bring the Visby Medical Sexual Health Click Test to healthcare organizations across the continuum of care, including urgent care, student health centers, women’s health facilities, and community health centers.

Visby’s PCR point-of-care device for STIs is an all-in-one unit that requires no separate instrument or reader. The Food and Drug Administration (FDA) cleared test is designed to provide accurate diagnosis in under 30 minutes and enables clinicians to discuss results and prescribe personalized treatment during the patient visit – rather than days later – eliminating the need for presumptive treatment.

“Our partnership with Visby demonstrates our commitment to bringing leading-edge medical innovations to the point of care that revolutionize patient care,” said Doug Sharpe, vice president of Lab Capital at Medline. “Winning several awards for design innovation and excellence, the Visby device is the first PCR test of its kind and gives clinicians a tool to help improve patient outcomes.”

According to a recent study in The Lancet Infectious Diseases, the Visby Medical Sexual Health Click Test is potentially the new gold standard for point-of-care tests for infectious diseases such as STIs in which rapid turnaround is key. As a finalist for the 2022 AACC Disruptive Technology Award, the Visby device has ~97% accuracy or greater for the detection of chlamydia, gonorrhea, and trichomonas, the three most common pathogens that can foster contagion and permanently damage a woman’s reproductive system if left untreated.

“Visby’s development of the world’s first instrument-free handheld PCR platform to accurately and rapidly test for a variety of serious infections is changing how healthcare is delivered, especially in urgent care and women’s health settings,” said Visby Medical Founder and CEO Adam de la Zerda. “Our partnership with Medline will help our innovative testing technology reach clinicians quickly, helping us improve STI containment, prevention, and treatment.”

Learn more about Visby Medical’s Sexual Health Click Test.

Share
Categories: Company News, Healthcare Segment News, Infection Prevention, Patient Experience

Medline Newsroom Staff

Medline Newsroom Staff

Medline's newsroom staff researches and reports on the latest news and trends in healthcare.

View All Stories From This Author